Q1 FY27 saw 19.1% revenue growth, driven by higher patient volumes, improved realizations, and strong Swasthfit and Suburban performance. EBITDA margin reached 31%, with robust cash reserves and continued investment in innovation and expansion.Based on Dr. Lal PathLabs Limited [LALPATHLAB] Q1 26/27…
Q1 FY27 saw 19.1% revenue growth, 28.6% EBITDA growth, and strong patient volume gains, driven by favorable test/geographic mix and CGHS/ECHS price hikes. Expansion continued in rural India and internationally, with new acquisitions and digital initiatives supporting future growth.Based on Dr. Lal…
Q1 FY27 saw record revenue growth of 19.1% year-over-year, with strong gains in patient and sample volumes and improved margins. Strategic investments in R&D, digital infrastructure, and rural outreach supported profitability and future growth.Original document: Dr. Lal PathLabs Limited [LALPATHLAB…
Revenue and profits grew year-over-year, with consolidated revenue at INR 7,977 million and profit at INR 1,322 million. Interim dividend of INR 5 per share declared, and acquisitions in Ghana and India approved to drive future growth.Original document: Dr. Lal PathLabs Limited [LALPATHLAB] Interim…
